Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018)

Autor: Xavier Pivot, Anne Doly, Julien Manson, L. Samelson, Paul Cottu, Olivier Aujoulat, Hugues Barletta, Nassera Chalabi, Bruno Coudert, David Pérol
Přispěvatelé: Département d'Oncologie Médicale [Institut Curie, Paris], Institut Curie [Paris], Département d'oncologie médicale [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Département cancer environnement (Centre Léon Bérard - Lyon), Centre Léon Bérard [Lyon], Université Clermont Auvergne (UCA), Centre Hospitalier René Dubos [Pontoise], Groupe hospitalier de la région de Mulhouse et Sud-Alsace, Hôpital privé Drôme Ardèche, groupe Ramsay générale de santé, site Pasteur, Roche France, CRLCC Paul Strauss, Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Adult
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Receptor
ErbB-2
[SDV]Life Sciences [q-bio]
Breast Neoplasms
Pharmacy
Antibodies
Monoclonal
Humanized
Young Adult
03 medical and health sciences
chemistry.chemical_compound
Antineoplastic Agents
Immunological
0302 clinical medicine
Breast cancer
Trastuzumab
Internal medicine
HER2
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
Molecular Targeted Therapy
Stage (cooking)
skin and connective tissue diseases
Reimbursement
Trastuzumab emtansine
Aged
Retrospective Studies
Aged
80 and over
Pertuzumab
Retrospective real-world data study
business.industry
Cancer
Middle Aged
medicine.disease
3. Good health
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Female
France
business
medicine.drug
Zdroj: European Journal of Cancer
European Journal of Cancer, 2020, 141, pp.209-217. ⟨10.1016/j.ejca.2020.10.012⟩
European Journal of Cancer, Elsevier, 2020, 141, pp.209-217. ⟨10.1016/j.ejca.2020.10.012⟩
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2020.10.012⟩
Popis: International audience; Background: There is a growing need for real-world data on cancer treatments usage, especially to assess compliance with recommendations. We developed a French project using hospital data to analyse evolution in the therapeutic strategies implemented in patients with human epidermal growth factor receptor 2 (HER2)-overexpressed (HER2+) breast cancer (BC) and exposed to injectable HER2-targeted therapies, i.e. trastuzumab, pertuzumab or trastuzumab emtansine (T-DM1).Patients and methods: Data from 26,350 women with BC were extracted in September 2018 from the Electronic Pharmacy Record systems of 120 French randomly recruited hospitals. Evolution in the treatments used, and combination regimens were described from 2011, in accordance with the BC stage and treatment line.Results: Overall, 21,119 patients treated since 2011 were analysed: 16,398 patients with early BC (eBC) and 6030 patients with metastatic BC (mBC) including patients treated at both stages. In eBC, 89.2% of patients received trastuzumab combined with at least taxanes (trastuzumab-taxane-anthracycline: 62.6%). Patients with mBC were treated in the first line (80.3%) and/or the second line (40.1%) and/or ≥ the third line (28.3%). After its approval in 2014, pertuzumab was first used in first-line therapy combinations in 67.4% of the total cases, while trastuzumab-taxane decreased from 47.2% to 9.2%. Similarly, T-DM1 was used as the second-line treatment in 53.8% of cases.Conclusions: Given recent changes in available treatments for patients with HER2+ BC, this large French project provides robust information on real-world evolution in therapeutic strategies. Our data suggest there is room for significant improvement in optimal drug utilisation. Such data will be useful to build drug-related indicators for future value-based pricing solutions.
Databáze: OpenAIRE
Externí odkaz: